is tirzepatide discontinued no - IscompoundedtirzepatideFDA-approved a shortage of Eli Lilly's obesity drug tirzepatide has been resolved Is Tirzepatide Discontinued? Understanding the Latest FDA Guidance and Compounding Pharmacy Regulations

Iscompoundedtirzepatidelegal The question of whether tirzepatide is discontinued has been a point of significant discussion, particularly concerning compounded versions of the medication. The U.S.Generally,no. After the FDA upheld its decision in December, the agency has given pharmacies a grace period to phase out compounded tirzepatide injections. Food and Drug Administration (FDA) has been actively involved in clarifying policies, especially as the shortage of GLP-1 medications like Mounjaro and Zepbound (the brand names for tirzepatide in diabetes and weight management respectively) has been resolved.

While the underlying active ingredient tirzepatide has no been officially discontinued by its manufacturer, Eli Lilly and Company, regulatory changes have impacted the availability of certain formulationsFDA's Removal of Semaglutide and the Evolving .... The tirzepatide injection shortage had been resolved, as confirmed by the FDA on December 19, 2024.2024年12月19日—The Food and Drug Administration on Thursday confirmed thata shortage of Eli Lilly's obesity drug tirzepatide has been resolved. This led to a shift in how compounded versions of the drug are handled.

The End of Compounded Tirzepatide

A key development is the directive from the FDA to compounding pharmacies concerning tirzepatide. The FDA formally announced the end of the tirzepatide shortage, and this has directly influenced the legality and availability of compounded versions. Compounding pharmacies were given a grace period to phase out these preparations. Specifically, compounding pharmacies were instructed that their production of tirzepatide must end by March 19, 2025. This deadline means that the ability of compounding pharmacies to legally manufacture generic versions of tirzepatide-based medications has ended2024年12月31日—The FDA announced compounded Tirzepatide productionmust end by March 19, 2025, citing improved availability of brand-name GLP-1 and GIP .... Various sources indicate that by March 19, 2025, compounding pharmacies were to stop making versions of tirzepatide.

This regulatory shift has led to some pharmacies, such as CVS Health, announcing that beginning July 1, 2025, their pharmacy benefit manager (PBM) division will drop tirzepatide (Zepbound; Eli Lilly and Co.) from their formularies. While not a discontinuation of the drug itself, this signifies a change in how patients may access and afford the medication through certain healthcare providers and insurance plans.

Why the Shift? Understanding the FDA's Role

The FDA's actions stem from the resolution of the drug shortage. When a shortage is declared over, especially in relation to approved medications, the agency often adjusts its policies regarding unapproved compounded alternativesZepbound copycats remain online despite FDA ban. The FDA's decision to remove tirzepatide from the shortage list was based on improved availability of the brand-name GLP-1 and GIP medications.

Concerns about compounded tirzepatide being banned, or disappearing, have been prevalent. While not a complete ban, the FDA's stance is that state-licensed compounding pharmacies must stop making most compound versions of GLP-1 drugs based on tirzepatideWhy Am I Not Losing Weight on Tirzepatide. This also affects other GLP-1 drugs, such as those containing semaglutideThe number of patients whodiscontinuedtakingtirzepatidealso increased as the dosage increased, with patients taking 15 mg having a 25% discontinuation ....

Tirzepatide Usage and Discontinuation in Clinical Settings

Beyond the regulatory landscape of compounding, it's also important to note that discontinuation of tirzepatide can occur in clinical practice. Research indicates that the discontinuation of tirzepatide is common in randomized controlled trials. Studies have explored the reasons for discontinuation of obesity pharmacotherapy, with tirzepatide or semaglutide, noting that treatment discontinuation is common among patients. Data suggests the number of patients who discontinued taking tirzepatide increased as the dosage increased, with patients taking 15 mg having a 25% discontinuation rate2025年3月19日—The FDA says compounding pharmacies have to stop makingtirzepatidebecause the agency has declared the yearlong Zepbound shortage over.. Adverse events (AEs) and other causes are cited as reasons for discontinuing tirzepatide in clinical trials, even when therapeutic benefits are evident.

Furthermore, a study published in December 2023 highlighted that for participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment showed different outcomesCompounded Zepbound alternatives disappear : Shots. This underscores the importance of sustained treatment for achieving and maintaining therapeutic goals.

What Patients Should Know

For individuals seeking tirzepatide, especially those who have relied on compounded versions, understanding these changes is crucial2025年5月14日—CVS Health announced that beginning July 1, 2025, its pharmacy benefit manager (PBM) division will drop tirzepatide (Zepbound; Eli Lilly and Co.) from its .... The availability of compounded tirzepatide has ended, and pharmacies now have until March 19 to cease production. While tirzepatide itself is not discontinued, access to compounded forms is being phased out.

Patients should consult with their healthcare providers to discuss available treatment options, the differences between brand-name tirzepatide (Mounjaro, Zepbound) and potential alternatives, and how these new regulations might affect their treatment plan. Exploring tirzepatide alternatives for weight loss may become a necessary step for some individuals. The tirzepatide injection shortage had been resolved, but the nuances of compounded versus approved formulations are critical to understand for ongoing care2025年3月21日—Compounding pharmacies were largely supposed to stop making versions oftirzepatidethis week, but it's still available on some popular ....

It is important to differentiate between the intentional discontinuation by a patient or provider and the regulatory cessation of compounded products. The FDA's clarification and updated policies aim to ensure patient safety and access to approved medications. The tirzepatide medication, as approved by the FDA concerning its shortage, remains available through prescribed channels.